JAGSNPHARM vs LAURUSLABS: Stock Comparison
LAURUS LABS is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a lower P/E, a higher dividend yield and faster revenue growth, while LAURUS LABS shows a higher ROE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 9; LAURUSLABS leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| Live Price | ₹215.2 | ₹2,321.5 |
| Day Change | -3.04% | 3.45% |
| Volume | 26,248 | 29.69 L |
| 52-Week High | ₹264.5 | ₹2,244 |
| 52-Week Low | ₹155 | ₹917.95 |
| Distance from 52W High | -18.64% | 3.45% |
Valuation
| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| Market Cap | ₹1,455 Cr | ₹1.26 L Cr |
| P/E Ratio | 32.35x | 110.86x |
| P/B Ratio | 6.09x | 22.87x |
| EPS | ₹2 | ₹6.8 |
| Book Value | ₹41.95 | ₹100.53 |
| Dividend Yield | 1.8% | 0.09% |
Growth
| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 5.3% |
| EPS Growth (TTM YoY) | 23.8% | 19.4% |
| Qtr Sales Growth | 0% | 11.85% |
| Qtr Profit Growth | 0% | 28.35% |
Profitability & Leverage
| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| ROE | 15.6% | 16.39% |
| ROCE | 16.48% | 13.68% |
| Net Margin | 15% | 13.76% |
| Operating Margin | 20.38% | 19.85% |
| Debt to Equity | 0x | 0.44x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | JAGSNPHARM | LAURUSLABS |
|---|---|---|
| Promoter Holding | 25.46%▼ 0.09 pp | 27.47% |
| FII Holding | 2.14%▼ 0.16 pp | 30.84%▲ 2.84 pp |
| DII Holding | 1.65%▲ 1.03 pp | 11.86%▼ 1.88 pp |
| Public Holding | 27.4%▼ 0.63 pp | 29.83%▼ 0.95 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and LAURUS LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.